Gabapentin – 8 reasons to use in pain management the reliable GABA analogue Review article
Article Sidebar
Published:
Sep 30, 2018
Keywords:
gabapentin, neuropathic pain, sensitization, safety, pharmacotherapy
Main Article Content
Abstract
Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. In symptomatic treatment in order to reduce the pain intensity the drugs acting at different levels of nervous system are recommended. One of the methods decreasing neuropathic pain intensity is inhibition of the release of neurotransmitters responsible for central sensitization, through acting on alfa-2-delta subunit of voltage gated calcium channels. Gababentin has such a mechanism of action. It is an effective drug, what has been confirmed in randomized clinical trials, and well tolerated by patients, therefore is a first line treatment in various neuropathic pain syndromes.
Article Details
How to Cite
Kocot-Kępska , M. (2018). Gabapentin – 8 reasons to use in pain management the reliable GABA analogue. Medycyna Faktow (J EBM), 11(3(40), 194-198. https://doi.org/10.24292/01.MF.0318.5
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bannister K., Qu C., Navratilova E. et al.: Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain 2017; 158(12): 2386-2395.
2. Chen J., Li L., Chen S.R. et al.: The a2d-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions. Cell Reports 2018; 22: 2307-2321.
3. Juarez-Salinas D.L., Braz J.M., Hamel K.A., Basbaum AI.: Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls. Pain Rep. 2018; 3(4): e659.
4. Szczudlik A. et al.: Rozpoznanie i leczenie bólu neuropatycznego: przegląd piśmiennictwa i zalecenia Polskiego Towarzystwa Badania Bólu i Towarzystwa Neurologicznego – część druga. Ból 2014; 15(3): 8-21.
5. Finnerup N.B., Attal N., Haroutounian S. et al.: Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162-173.
6. Attal N., Cruccu G., Baron R. et al.: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol. 2010; 17: 1113-1123.
7. Thompson D.F., Brooks K.G.: Gabapentin therapy of hiccups. Ann Pharmacother. 2013; 47(6): 897-903.
8. Wijemanne S., Ondo W.: Restless Legs Syndrome: clinical features, diagnosis and a practical approach to management. Pract. Neurol. 2017; 17(6): 444-452.
9. Mason B.J., Quello S., Shadan F.: Gabapentin for the treatment of alcohol use disorder. Expert Opin. Investig. Drugs 2018; 27(1): 113-124.
10. Guttuso T. Jr.: Gabapentin’s anti-nausea and anti-emetic effects: a review. Exp. Brain Res. 2014; 232(8): 2535-2539.
11. Houghton K.T., Forrest A., Awad A. et al.: Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. BMJ Open 2017; 7(3): e013433.
12. Zhang M., Gao C.X., Ma K.T et al.: A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. Biomed. Res. Int. 2018; 2018: 7474207.
13. Wiffen P.J., Derry S., Bell R.F. et al.: Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 2017 Jun 9.
14. Pop-Busui R., Boulton A.J., Feldman E.L. et al.: Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136-154.
15. Hesami O., Gharagozli K., Beladimoghadam N. et al.: The Efficacy of Gabapentin in Patients with Central Post-stroke Pain. Iran J. Pharm. Res. 2015; 14(supl.): 95-101.
16. Mehta S., McIntyre A., Dijkers M. et al.: Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis. Arch. Phys. Med. Rehabil. 2014; 95(11): 2180-2186.
17. Mishra S., Bhatnagar S., Goyal G.N. et al.: A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am. J. Hosp. Palliative Care 2012; 29(3): 177-182.
18. Wordliczek J., Kotlińska-Lemieszek A., Leppert W. et al.: Farmakoterapia bólu u chorych na nowotwory – zalecenia Polskiego Towarzystwa Badania Bólu, Polskiego Towarzystwa Medycyny Paliatywnej, Polskiego Towarzystwa Onkologicznego, Polskiego Towarzystwa Medycyny Rodzinnej, Polskiego Towarzystwa Anestezjologii i Intensywnej Terapii. Ból 2017; 18(3): 11-53.
19. Chang C.Y., Challa C.K., Shah J., Eloy J.D.: Gabapentin in acute postoperative pain management. Biomed. Res. Int. 2014; 2014: 631756.
20. Dworkin R.H., O’Connor A.B., Audette J. et al.: Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc. 2010; 85(supl. 3): S3-S14.
21. Lussier D.: Pain Pharmacotherapy in Older Patients. W: Pain 2016: Refresher Courses, 16th World Congress on Pain.
2. Chen J., Li L., Chen S.R. et al.: The a2d-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions. Cell Reports 2018; 22: 2307-2321.
3. Juarez-Salinas D.L., Braz J.M., Hamel K.A., Basbaum AI.: Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls. Pain Rep. 2018; 3(4): e659.
4. Szczudlik A. et al.: Rozpoznanie i leczenie bólu neuropatycznego: przegląd piśmiennictwa i zalecenia Polskiego Towarzystwa Badania Bólu i Towarzystwa Neurologicznego – część druga. Ból 2014; 15(3): 8-21.
5. Finnerup N.B., Attal N., Haroutounian S. et al.: Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162-173.
6. Attal N., Cruccu G., Baron R. et al.: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol. 2010; 17: 1113-1123.
7. Thompson D.F., Brooks K.G.: Gabapentin therapy of hiccups. Ann Pharmacother. 2013; 47(6): 897-903.
8. Wijemanne S., Ondo W.: Restless Legs Syndrome: clinical features, diagnosis and a practical approach to management. Pract. Neurol. 2017; 17(6): 444-452.
9. Mason B.J., Quello S., Shadan F.: Gabapentin for the treatment of alcohol use disorder. Expert Opin. Investig. Drugs 2018; 27(1): 113-124.
10. Guttuso T. Jr.: Gabapentin’s anti-nausea and anti-emetic effects: a review. Exp. Brain Res. 2014; 232(8): 2535-2539.
11. Houghton K.T., Forrest A., Awad A. et al.: Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. BMJ Open 2017; 7(3): e013433.
12. Zhang M., Gao C.X., Ma K.T et al.: A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. Biomed. Res. Int. 2018; 2018: 7474207.
13. Wiffen P.J., Derry S., Bell R.F. et al.: Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 2017 Jun 9.
14. Pop-Busui R., Boulton A.J., Feldman E.L. et al.: Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136-154.
15. Hesami O., Gharagozli K., Beladimoghadam N. et al.: The Efficacy of Gabapentin in Patients with Central Post-stroke Pain. Iran J. Pharm. Res. 2015; 14(supl.): 95-101.
16. Mehta S., McIntyre A., Dijkers M. et al.: Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis. Arch. Phys. Med. Rehabil. 2014; 95(11): 2180-2186.
17. Mishra S., Bhatnagar S., Goyal G.N. et al.: A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am. J. Hosp. Palliative Care 2012; 29(3): 177-182.
18. Wordliczek J., Kotlińska-Lemieszek A., Leppert W. et al.: Farmakoterapia bólu u chorych na nowotwory – zalecenia Polskiego Towarzystwa Badania Bólu, Polskiego Towarzystwa Medycyny Paliatywnej, Polskiego Towarzystwa Onkologicznego, Polskiego Towarzystwa Medycyny Rodzinnej, Polskiego Towarzystwa Anestezjologii i Intensywnej Terapii. Ból 2017; 18(3): 11-53.
19. Chang C.Y., Challa C.K., Shah J., Eloy J.D.: Gabapentin in acute postoperative pain management. Biomed. Res. Int. 2014; 2014: 631756.
20. Dworkin R.H., O’Connor A.B., Audette J. et al.: Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc. 2010; 85(supl. 3): S3-S14.
21. Lussier D.: Pain Pharmacotherapy in Older Patients. W: Pain 2016: Refresher Courses, 16th World Congress on Pain.